GlassScriptPhysician profile
Thomas C Aiello
NPI 1366444754
$3,335.69
in general payments reported to CMS, 2019-2025
23 companies · $817 in 2025
The $817 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $555 · 2020: $195 · 2021: $308 · 2022: $375 · 2023: $417 · 2024: $669 · 2025: $817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,903.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,902.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $559.64 | 2022-2025 | Argos, Voyager Dslt, Hydrus Microstent |
| Bausch & Lomb Americas INC. | $337.57 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Oyster Point Pharma, INC. | $256.48 | 2022-2025 | Tyrvaya, Ryzumvi |
| Glaukos Corporation | $251.89 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $216.27 | 2024-2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $215.89 | 2019-2022 | |
| Biotissue Holdings INC. | $183.82 | 2023 | |
| Novartis Pharmaceuticals Corporation | $174.36 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $168.98 | 2023-2025 | Tecnis Iol, Tecnis Iol |
| Ivantis, INC | $138.50 | 2021 | |
| New World Medical,INC. | $134.74 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $126.11 | 2019-2021 | |
| Harrow Eye, LLC | $99.62 | 2024-2025 | Vevye, Iheezo |
| Astellas Pharma US INC | $94.96 | 2023-2025 | Izervay |
| Sun Pharmaceutical Industries INC. | $70.59 | 2019-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $65.96 | 2021-2022 | |
| Dompe US, INC. | $65.88 | 2024-2025 | Oxervate |
| Sight Sciences, INC. | $60.10 | 2022 | |
| Mallinckrodt Hospital Products INC. | $30.92 | 2024 | Acthar |
| Shire North American Group INC | $29.88 | 2019 | |
| Aerie Pharmaceuticals, INC. | $20.80 | 2021 | |
| Thea Pharma INC. | $18.61 | 2024 | Iyuzeh |
| Ocular Therapeutix, INC. | $14.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Aiello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.